Interestingly, tamoxifen not only inhibits estrogen signaling, but it also reduces serum prolactin levels [55] and prevents prolactin binding to its receptor [56], raising the possibility that a reduction in STAT5 activity was responsible for reduced tumor formation in this setting. Here, PRL is linked to neoplasm.